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quency of ofﬁce-based visits was the primary driver of increased
psoriasis-speciﬁc health care costs (p = 0.02). There were no sig-
niﬁcant differences in health care costs among patients using dif-
ferent types of psoriasis medications. CONCLUSIONS: Cost
towards psoriasis medications account for most of the psoriasis-
speciﬁc health care costs. Increase in frequency of ofﬁce-based
visits seems to be the primary driver of increased psoriasis-
speciﬁc health care costs.
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OBJECTIVE: There have been tremendous advances in treat-
ment for patients with extensive psoriasis. Many of the newer
treatments have shown great promise, but at a signiﬁcant cost to
the health care system. Ofﬁce phototherapy treatments continue
to be an excellent ﬁrst choice because of high safety, good efﬁ-
cacy and relatively low cost. Unfortunately, ofﬁce phototherapy
may not be feasible for many patients. Home UVB offers another
option for these patients. The purpose of this study is to 
assess the long-term ﬁnancial cost of home UVB treatment.
METHODS: We constructed a societal cost model for owning
and operating a home UVB unit over a period of 30 years. This
model included both direct and indirect costs associated with
home treatment and periodic follow-up. These data were com-
pared to the cost of other monotherapies for extensive psoriasis.
RESULTS: The discounted present value of 30 years of treatment
with home UVB was approximately $10,000. The initial one
time cost of the home UVB device, approximately $2000, is 
only a small component of the lifetime cost. Over the same 
treatment period, methotrexate had an estimated cost of
$23,530. The cost of one year of biologic treatment exceeded the
lifetime cost of home UVB. CONCLUSIONS: Home UVB is not
for every patient with psoriasis. Highly inﬂammatory lesions or
signiﬁcant co-existent arthritis are just two of many reasons 
that systemic treatments may be required. Nevertheless, home
UVB offers a very cost-efﬁcient approach to treatment. Insurers
should make this option more available to patients with 
extensive psoriasis.
PSK5
COST-UTILITY ANALYSIS OF AMEVIVETM (ALEFACEPT) IN THE
TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE
PSORIASIS
Iskedjian M1, Barkovsky L1, Desjardins O1,Walker JH2, Dorkalam M3,
Shear N4, Einarson TR4
1PharmIdeas Research and Consulting Inc, Oakville, ON, Canada;
2Brock University, St. Catharines, ON, Canada; 3Biogen Idec Canada
Inc, Mississauga, ON, Canada; 4University of Toronto,Toronto, ON,
Canada
OBJECTIVES: Quality of life concerns (social discomfort,
embarrassment, etc.) are an important aspect for patients 
with moderate-to-severe plaque psoriasis. Alefacept is a new 
biological found effective for treatment. This cost-utility 
analysis was conducted to compare standard therapies to ale-
facept. METHODS: A two-year Markov model was developed.
Response was assessed using the Psoriasis Area and Severity
Index Score (PASI) 75. Patient preferences were expressed in util-
ities. Treatments with high utilities represented the greatest
health improvement. Treatment comparators were methotrexate,
cyclosporine, and phototherapy (with/without acitretin). Data,
resource use, and health-state utilities were derived from litera-
ture, expert clinical opinion and a cost of illness (COI) study.
Costs (Canadian dollars) were obtained from standard published
lists. Separate Ontario Ministry of Health (MoH) and societal
(SOC) perspectives were conducted. RESULTS: In the MoH base
case, expected costs were $7,790, $9,042, $10,635, $32,859 for
methotrexate, phototherapy, cyclosporine and alefacept, respec-
tively. Response-days associated with each treatment were 175,
78, 175 and 247 days respectively. The cost of each additional
QALY (Quality-adjusted life-year), compared to methotrexate,
was $97,887. For the SOC base case, each additional QALY was
$96,426. Phototherapy and cyclosporine were dominated. These
results used the PASI 75. However, the PASI 50 may be more
clinically relevant for dermatologists and patients. Using the
PASI 50, alefacept had the highest cost and highest utility of
$92,043 (MoH) and $88,391 (SOC) per QALY. Psoriasis is a
chronic disease, and it is important to assess cost-utilities over
time. After ﬁve years, the QALY for the MoH perspective was
$31,412. SOC results were similar. Using the PASI 50 response
rates, the cost per QALY after three years was similar to that of
the PASI 75 after ﬁve years. CONCLUSION: Alefacept compares
favourably to methotrexate, the current standard of treatment,
and is cost-effective in several scenarios while cyclosporine and
phototherapy were dominated.
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OBJECTIVES: To aid in the interpretation of scores on the
QoLIAD and provide information on what represents meaning-
ful change in QoLIAD scores. METHODS: The QoLIAD is a
25-item needs-based instrument assessing the quality of life
(QoL) of individuals with atopic dermatitis (AD). It has simple
“Yes”/“No” response options and scores range from zero to 25.
Data collected from patients in a six-month, multinational, 
open-label study were analysed. Effect Size (ES), Standardised
Response Mean (SRM), the Responsiveness Statistic (RS) and
Standard Error of Measurement (SEM) were calculated. An
anchor-based Minimal Important Difference (MID); which pro-
vides an estimate of clinical meaningfulness was derived by mea-
suring QoL change accompanying changes in disease severity on
a six-point Investigator’s Global Assessment (IGA). The IGA
ranged from zero (clear) to ﬁve (very severe disease). QoLIAD
scores were also anchored to questions asking patients if they
would continue to use or recommend the study treatment.
RESULTS: In total, 264 AD patients completed the QoLIAD
(112/42% male; mean age 37 +/- 14.3; baseline mean QoLIAD
= 7.1 +/- 5.4; two-months = 5.8 +/- 5.6; six-months = 4.9 +/-
5.5). Changes from baseline were signiﬁcant (p < 0.001,
Wilcoxon test). According to ES, changes of 1.1, 2.7, and 4.3
represent small, moderate and large changes in QoLIAD scores,
respectively. One SEM = 1.71; 1.96 SEM = 3.35. Mean change
scores of patients who would deﬁnitely continue to use and def-
initely recommend product was 1.8 and 2.2, respectively. A two-
point improvement in IGA scores equated to a 2.1 (baseline
two-months) and 3.1 (baseline six-months) change in QoLIAD
scores. CONCLUSION: Distribution- and anchor-based
methods of interpreting instrument scores suggest that a change
in QoLIAD scores of between two and three can be considered
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meaningful. This equated to the change found following six-
months of treatment.
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OBJECTIVES: Monetary cost, positive values truncated at zero,
violates normality assumption when used as the dependent 
variable in ordinary least squares (OLS) regressions. Log trans-
formation of cost removes the skewness, but the resulting coef-
ﬁcients are not directly interpretable as raw dollars. Simply
taking exponent of ﬁtted regression coefﬁcients causes retrans-
formation bias. Duan’s nonparametric smearing estimator
factors into the mean of the anti-log of the residuals, thus 
correcting retransformation bias. The goal of this analysis is to
apply Duan’s smearing technique to retransform logged costs to
evaluate the incremental cost of ChHD using claims data from
an HMO. METHODS: A 13-item self-assessment questionnaire
identifying ChHD and its severity was developed, validated, and
mailed to 1,380 randomly selected members of a Massachusetts
HMO. Average monthly costs for questionnaire respondents
were calculated by the sum of approved and co-payment
amounts from claims ﬁled between April 1, 2001–December 31,
2003 divided by months of observation. OLS regression of log-
arithm of cost was used, with covariates consisting of a ChHD
dummy, and demographic and co-morbid factors. Using Duan’s
estimator, average monthly incremental cost of ChHD was cal-
culated by multiplying percentage cost increase for ChHD from
the OLS regression by predicted average monthly cost for Non-
ChHD patients (which is the average cost after removing the
effect of the ChHD dummy). RESULTS: 140 of 507 question-
naire respondents were identiﬁed as ChHD. Univariate compar-
ison showed no statistical difference in monthly cost between the
ChHD and Non-ChHD groups (Non-ChHD, $326.98 ± $29.52,
ChHD $270.87 ± $23.59, p = 0.1383). A skewness and kurto-
sis test rejected normality. However, multivariate analysis
showed that ChHD patients had a statistically signiﬁcant
monthly cost increase of 25.2%( ±2.5%) compared to Non-
ChHD (p < 0.001), amounting to an average monthly incre-
mental cost of ChHD of $70.69 (±$7.00) per patient.
CONCLUSIONS: Duan’s smearing estimator may be valid for
inferring incremental cost in OLS regression models of logarithm
of cost.
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OBJECTIVES: Atopic dermatitis (AD) is a common childhood
chronic skin condition. Despite high disease prevalence, up to
20% in some populations, little information is available regard-
ing the burden of disease to children and parent/caregivers. 
An objective of this study was to assess the impact of AD on
parents’/caregivers’ quality-of-life. METHODS: In total, 414 AD
patients, between 2–12 years old were identiﬁed through a ret-
rospective review of outpatient billing records from January,
2001 to December, 2004 from two large physician practices and
were contacted to enroll in the study. Data collected included
patient demographics, comorbidities, treatments, and health 
care resource use. Parents also completed the Parent’s Index of
Quality of Life-Atopic Dermatitis (PIQoL-AD), a 28-item, vali-
dated questionnaire evaluating parents’ needs-based quality-of-
life. Total PIQoL-AD scores can range from zero to 28, with a
higher score indicating greater impaired quality-of-life. One-way
analysis of variance was used to determine statistical signiﬁcance.
RESULTS: Mean patient age was 6.7 (SD ± 3.3) years and 55%
of patients were males. Mean duration and treatment of illness
were 3.0 ± 2.2 years and 20.7 ± 21.4 months, respectively.
Parents’ assessment of disease severity indicated that 82% of
patients had mild AD and 13% of patients had moderate AD.
Patients reporting at least one ﬂare experienced 2.8 ± 2.3 ﬂares
per month; mean duration of ﬂares was 5.2 ± 7.0 days. Disease
ﬂares negatively impacted parents’ quality-of-life. PIQoL-AD
scores worsened among those parents whose child had disease
ﬂares. Mean PIQoL-AD scores were statistically signiﬁcantly
higher (5.9 ± 5.4 vs. 3.0 ± 3.6, p < 0.0001) for those parents
whose child had disease ﬂares compared to those who did 
not have disease ﬂares. CONCLUSIONS: Study ﬁndings will
improve our understanding of the impact of AD on children and
their parents/caregivers and may enhance treatment effects, 
clinical outcomes, and patient and parent/caregiver education.
Further investigation is needed to understand the impact of
atopic dermatitis on parents’ quality-of-life.
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OBJECTIVES: The prevalence of chronic hand dermatitis
(ChHD) and its impact on patient-reported outcomes, including
quality of life (QoL), work and activity impairment, were eval-
uated in a managed care organization (MCO). To date, few
studies have investigated ChHD using a general population-
based approach. METHODS: A validated cross-sectional
patient-reported survey was mailed to 1380 members of a Mass-
achusetts MCO. The survey consisted of: a 13-item clinical ques-
tionnaire identifying ChHD based on signs and symptoms of
dermatitis related to hands, treatment response, and diagnoses
of exclusion; the Skindex-29, a 29-question dermatology-speciﬁc
QoL instrument; and the Work Productivity and Activity Impair-
ment (WPAI) instrument validated for ChHD. Those receiving
the survey were randomly sampled from the general MCO pop-
ulation and a subset population with ≥ two medical claims with
a dermatitis or eczema diagnosis (ICD-9 692 or 691.8). ChHD
patients were compared to patients with other skin conditions
and to Non-ChHD patients to assess their relative QoL and
WPAI measures, respectively. RESULTS: Based on the survey
respondents (36.7% response rate), the prevalence of ChHD 
was 17.5% in the MCO general population, a rate much higher
than previously found (2–12%). QoL and WPAI measures for
the ChHD patients were signiﬁcantly worse than those for their
comparison groups (Skindex score: ChHD = 30.33 ± 17.51,
Other Skin Conditions = 20.05 ± 16.68; Work Impairment:
ChHD = 29.33%, Non-ChHD = 6.85%; Activity Impairment:
ChHD = 33.78%, Non-ChHD = 17.32%; all p < 0.0001).
